Structure via PubChem · Public domain (PubChem)
apricitabine
Sign in to saveApricitabine (INN, codenamed AVX754 and SPD754, sometimes abbreviated to ATC) is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine.
Chemical data
- Formula
- C8H11N3O3S
- Molecular weight
- 229.26 g/mol
- IUPAC name
- 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one
- SMILES
- C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N
- InChIKey
- RYMCFYKJDVMSIR-RNFRBKRXSA-N
- XLogP
- -1.2
- Polar surface area
- 113 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- HIV infection
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 229.052
Show 4 more facts
- chemical formula
- C₈H₁₁N₃O₃S
- canonical SMILES
- C1C(SC(O1)CO)N2C=CC(=NC2=O)N
- isomeric SMILES
- C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N
- Commons category
- Apricitabine
Sources (2)
via Wikidata · CC0
~4 min read
Encyclopedic overview
5 sectionsContents
- History
- Dosage
- Adverse effects
- Drug resistance
- References
Apricitabine (INN, codenamed AVX754 and SPD754, sometimes abbreviated to ATC) is an experimental nucleoside reverse transcriptase inhibitor (NRTI) against HIV. It is structurally related to lamivudine and emtricitabine, and, like these, is an analogue of cytidine.
==History== It was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold to Shire Pharmaceuticals (where apricitabine was called SPD754). Shire then sold the rights to develop the drug to Avexa Pharmaceuticals, an Australian pharmaceutical company. , apricitabine has closed its phase III clinical trial, and has been granted fast track status by the United States Food and Drug Administration.
Excerpted from Wikipedia’s “apricitabine” article, available under the CC BY-SA 4.0 licence.